$10.94
-1.14(-9.44%)
Mkt Cap $776M
$2.97
$17.18
52-Week Range
At a Glance
AI-generatedOmeros reported a net loss of -$3.4M and free cash flow of -$116.2M in FY2025, reflecting ongoing operational cash needs despite strategic transactions reshaping liquidity and pipeline focus.
Revenue breakdown: PDE7 (100%).
8-K
Omeros Corporation reported Q4 and full-year 2025 financial results, including $86.5 million Q4 net income driven by $237.6 million zaltenibart transaction gain with Novo Nordisk, FDA approval of YARTEMLEA, and strengthened balance sheet with $171.8 million cash.$776M
Market Cap
—
Revenue
-$130M
Net Income
Employees202
Fundamentals
How The Business Makes Money
Revenue by Segment
PDE7100%($900.0K)
Activity
Analyst View
Company Profile
CIK0001285819
ISINUS6821431029
CUSIP682143102
Phone206 676 5000
AddressThe Omeros Building, Seattle, WA, 98119, US
SEC EDGAR